KRAS and colorectal carcinoma: SLC25A22 silencing in KRAS-mutated CRC cell lines reduces glutamine metabolism, as revealed by a reduction in TCA cycle intermediates including succinate, fumarate, malate, oxaloacetate, and aspartate, and this was rescued by aspartate supplementation [67].